Targeted Medical Pharma (United States)

Recent papers from Targeted Medical Pharma (United States)

1. Development and Validation of a Six-Gene Signature of Myeloid Antigen Presentation Dysfunction Based on Single-Cell and Multi-Cohort Transcriptomics for Predicting Prognosis and Recurrence of Hepatocellular CarcinomaCancer Informatics · 2026
2. Correction: The immune microenvironment in endometrial carcinoma: mechanisms and therapeutic targetingSHILAP Revista de lepidopterología · 2026
3. Tyrer–Cuzick Lifetime Risk Is Not Associated With Non‐BRCA1/2 Pathogenic Variants for Breast CarcinomaThe Breast Journal · 2026
4. Family medicine residents’ perspectives on shared decision-making: A mixed methods studyPatient Education and Counseling · 2024
5. Tyrer-Cuzick Lifetime Risk is Not Associated with Non-BRCA1/2 Pathogenic Variants for Breast Carcinoma2024
6. Cost-effectiveness of precision molecular diagnostic tests for stage II colorectal cancerAnnals of Translational Medicine · 2022
7. Evaluating the Quality of the Economic Evidence in Colorectal Cancer Genomics StudiesPersonalized Medicine · 2022
8. Age-Independent Preoperative Chemosensitivity and 5-Year Outcome Determined by Combined 70- and 80-Gene Signature in a Prospective Trial in Early-Stage Breast CancerAnnals of Surgical Oncology · 2022
9. Pharmacoepidemiology: A time for a new multidisciplinary approach to precision medicinePharmacoepidemiology and Drug Safety · 2021
10. Personalized Medicine and the Practice of Medicine in the 21st CenturyMcGill Journal of Medicine · 2020
11. Factors affecting the efficacy of gemcitabine and nab-paclitaxel (paclitaxel + albumin) combination in the Russian patient population: results of a multicenter retrospective studyMeditsinskiy sovet = Medical Council · 2019
12. Open science precision medicine in Canada: Points to considerFACETS · 2019
13. Underdiagnosis of Hereditary Breast Cancer: Are Genetic Testing Guidelines a Tool or an Obstacle?Journal of Clinical Oncology · 2018
14. Evidence that Formulations of the Selective MAO-B Inhibitor, Selegiline, which Bypass First-Pass Metabolism, also Inhibit MAO-A in the Human BrainNeuropsychopharmacology · 2014
15. Cancer patients’ acceptance, understanding, and willingness-to-pay for pharmacogenomic testingPharmacogenetics and Genomics · 2014
16. Administration of an Amino Acid–Based Regimen for the Management of Autonomic Nervous System Dysfunction Related to Combat-Induced IllnessJournal of Central Nervous System Disease · 2014
17. Twice Daily Versus Once Nightly Dosing of Pregabalin for Fibromyalgia: A Double‐Blind Randomized Clinical Trial of Efficacy and SafetyArthritis Care & Research · 2013
18. Herbal compound triptolide synergistically enhanced antitumor activity of vasostatin120–180Anti-Cancer Drugs · 2013
19. Cholinergic Autonomic Dysfunction in Veterans With Gulf War IllnessJAMA Neurology · 2012
20. A Method to Measure Clinical Practice Patterns of Breast Cancer Genomic Diagnostics in Health SystemsPersonalized Medicine · 2012